Jeffrey A. Sosman

127.5k total citations · 14 hit papers
347 papers, 28.5k citations indexed

About

Jeffrey A. Sosman is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Jeffrey A. Sosman has authored 347 papers receiving a total of 28.5k indexed citations (citations by other indexed papers that have themselves been cited), including 244 papers in Oncology, 149 papers in Molecular Biology and 100 papers in Immunology. Recurrent topics in Jeffrey A. Sosman's work include Cancer Immunotherapy and Biomarkers (130 papers), Melanoma and MAPK Pathways (101 papers) and CAR-T cell therapy research (88 papers). Jeffrey A. Sosman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (130 papers), Melanoma and MAPK Pathways (101 papers) and CAR-T cell therapy research (88 papers). Jeffrey A. Sosman collaborates with scholars based in United States, Australia and France. Jeffrey A. Sosman's co-authors include Antoni Ribas, Douglas B. Johnson, Igor Puzanov, Grant A. McArthur, Michael B. Atkins, Keith T. Flaherty, Paul B. Chapman, Kevin B. Kim, K. B. Nolop and Vernon K. Sondak and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Jeffrey A. Sosman

343 papers receiving 27.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

2007 2.8k citations Piotr Tomczak, Robert A. Figlin et al. profile →
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 2.6k citations Igor Puzanov, Kevin B. Kim et al. profile →
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

2009 1.7k citations Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology profile →
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 1.6k citations Ramin Nazarian, Hubing Shi et al. profile →
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

1997 684 citations Michael B. Atkins, Jeffrey A. Sosman et al. profile →
High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

2001 653 citations Jeffrey A. Sosman et al. Journal of Clinical Oncology profile →
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

2016 604 citations Douglas B. Johnson, Alexander N. Shoushtari et al. profile →
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

2004 598 citations Jeffrey A. Sosman, Kim Margolin et al. Journal of Clinical Oncology profile →
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

2012 470 citations Hubing Shi, Gatien Moriceau et al. profile →
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

2015 412 citations Willy Hugo, Hubing Shi et al. profile →
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

2016 409 citations David F. McDermott, Jeffrey A. Sosman et al. Journal of Clinical Oncology profile →
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

2019 409 citations F. Stephen Hodi, David F. McDermott et al. profile →
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

2019 405 citations Douglas B. Johnson, Jeffrey A. Sosman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey A. Sosman United States	73	16.2k	15.5k	8.3k	6.9k	5.0k	347	28.5k
Grant A. McArthur Australia	74	15.0k 0.9×	15.2k 1.0×	5.4k 0.6×	3.8k 0.5×	3.1k 0.6×	395	26.8k
Georgina V. Long Australia	85	25.4k 1.6×	16.6k 1.1×	5.2k 0.6×	9.2k 1.3×	3.5k 0.7×	684	34.4k
Keith T. Flaherty United States	92	24.8k 1.5×	23.3k 1.5×	6.3k 0.8×	7.1k 1.0×	5.7k 1.1×	518	39.7k
Paolo A. Ascierto Italy	75	18.1k 1.1×	11.4k 0.7×	3.5k 0.4×	7.1k 1.0×	2.5k 0.5×	757	25.2k
Neal Rosen United States	100	12.2k 0.8×	24.7k 1.6×	5.7k 0.7×	3.0k 0.4×	4.2k 0.8×	255	34.8k
Richard A. Scolyer Australia	84	21.3k 1.3×	13.3k 0.9×	3.8k 0.5×	6.6k 1.0×	4.3k 0.9×	707	30.6k
David B. Solit United States	82	10.6k 0.7×	15.6k 1.0×	5.6k 0.7×	2.4k 0.3×	4.8k 1.0×	365	26.2k
Michael B. Atkins United States	91	25.3k 1.6×	16.0k 1.0×	12.6k 1.5×	12.0k 1.7×	6.3k 1.3×	577	40.7k
Martin Gore United Kingdom	78	14.4k 0.9×	12.9k 0.8×	9.0k 1.1×	3.6k 0.5×	4.9k 1.0×	382	29.5k
Omid Hamid United States	68	21.3k 1.3×	8.0k 0.5×	4.9k 0.6×	9.8k 1.4×	1.9k 0.4×	414	26.3k

Countries citing papers authored by Jeffrey A. Sosman

Since Specialization

Citations

This map shows the geographic impact of Jeffrey A. Sosman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Sosman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Sosman more than expected).

Fields of papers citing papers by Jeffrey A. Sosman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey A. Sosman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Sosman. The network helps show where Jeffrey A. Sosman may publish in the future.

Co-authorship network of co-authors of Jeffrey A. Sosman

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey A. Sosman. A scholar is included among the top collaborators of Jeffrey A. Sosman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey A. Sosman. Jeffrey A. Sosman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Atkins, Michael B., Opeyemi A. Jegede, Naomi B. Haas, et al.. (2023). Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for ImmunoTherapy of Cancer. 11(3). e004780–e004780. 19 indexed citations

Hamid, Omid, Luciana Molinero, Christopher R. Bolen, et al.. (2019). Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research. 25(20). 6061–6072. 58 indexed citations

Stout, Molly J., et al.. (2019). Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature. Melanoma Research. 30(3). 313–316. 24 indexed citations

Wongchenko, Matthew, Grant A. McArthur, Brigitte Dréno, et al.. (2017). Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clinical Cancer Research. 23(17). 5238–5245. 28 indexed citations

Song, Chunying, Marco Piva, Lu Sun, et al.. (2017). Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discovery. 7(11). 1248–1265. 109 indexed citations

Zhai, Lijie, Erik Ladomersky, Kristen L. Lauing, et al.. (2017). Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clinical Cancer Research. 23(21). 6650–6660. 144 indexed citations

Algazi, Alain P., Katy K. Tsai, Alexander N. Shoushtari, et al.. (2016). Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies. Cancer. 122(21). 3344–3353. 265 indexed citations

Joseph, Richard W., Chengwei Peng, Fei Ye, et al.. (2016). Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. Cancer Immunology Research. 4(7). 569–573. 16 indexed citations

Greenplate, Allison R., Douglas B. Johnson, Mikaël Roussel, et al.. (2016). Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti–PD-1 Therapy. Cancer Immunology Research. 4(6). 474–480. 16 indexed citations

10.

Liu, Yan, Oriana E. Hawkins, Anna E. Vilgelm, et al.. (2015). Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Clinical Cancer Research. 21(23). 5338–5348. 20 indexed citations

11.

Cohen, Daniel N., Aaron C. Shaver, Liping Du, et al.. (2015). Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. Clinical Cancer Research. 21(11). 2624–2634. 23 indexed citations

12.

Xia, Junfeng, Peilin Jia, Katherine E. Hutchinson, et al.. (2014). A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance. Molecular Cancer Therapeutics. 13(7). 1918–1928. 65 indexed citations

13.

Shi, Hubing, Willy Hugo, Xiangju Kong, et al.. (2013). Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery. 4(1). 80–93. 715 indexed citations breakdown →

14.

Kim, Kevin B., Richard Kefford, Anna C. Pavlick, et al.. (2012). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology. 31(4). 482–489. 356 indexed citations

15.

Shi, Hubing, Gatien Moriceau, Xiangju Kong, et al.. (2012). Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery. 2(5). 414–424. 75 indexed citations

16.

Su, Yingjun, Anna E. Vilgelm, Mark C. Kelley, et al.. (2012). RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. Clinical Cancer Research. 18(8). 2184–2198. 47 indexed citations

17.

Kim, Kevin B., Jeffrey A. Sosman, John P. Fruehauf, et al.. (2011). BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. Journal of Clinical Oncology. 30(1). 34–41. 148 indexed citations

18.

Motzer, Robert J., Thomas E. Hutson, Piotr Tomczak, et al.. (2009). Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(22). 3584–3590. 1711 indexed citations breakdown →

19.

Su, Yingjun, Katayoun I. Amiri, Linda W. Horton, et al.. (2009). A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets. Clinical Cancer Research. 16(1). 348–357. 29 indexed citations

20.

Rini, Brian I., M. Dror Michaelson, Jonathan E. Rosenberg, et al.. (2008). Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 26(22). 3743–3748. 321 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact